Trial Profile
Clinical Trials Insight: 700051726
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2011
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Sponsors Nippon Shinyaku
- 21 Jan 2011 Azacitidine has been approved for treatment of myelodysplastic syndromes based on results of this and other trials.
- 16 Dec 2009 New trial record.